"Ternary Therapeutics is developing a technology platform that combines machine learning, physics-based molecular modelling and rapid laboratory validation to design molecular glues - a promising but still emerging category of drugs that can target proteins previously considered undruggable."
"Unlike traditional medicines, which typically work by binding directly to a target protein and inhibiting its function, molecular glues operate by bringing two proteins together to trigger the destruction or modification of disease-causing proteins. This mechanism has become one of the most exciting areas of drug discovery in recent years, particularly in fields such as cancer, autoimmune disorders and neurological diseases."
"Ternary aims to change that dynamic by applying computational methods and artificial intelligence to turn molecular glue discovery into a systematic engineering process. The company's platform uses AI models to predict how proteins behave within the body and identify potential molecules capable of binding them together."
Ternary Therapeutics, a London-based biotechnology startup founded in November 2024, has raised £3.6 million in seed funding led by daphni with support from Pace Ventures, i&i Biotech Fund, and the UK Innovation & Science Seed Fund. The company develops an AI platform combining machine learning, physics-based molecular modelling, and laboratory validation to design molecular glues—drugs that bring two proteins together to trigger destruction or modification of disease-causing proteins. Unlike traditional medicines that directly inhibit target proteins, molecular glues operate through protein-protein interactions. Most molecular glues have been discovered accidentally, but Ternary aims to systematize discovery through computational methods and AI. The platform uses AI models to predict protein behavior and identify binding molecules, with experimental results feeding back into the system for continuous improvement.
#molecular-glues #artificial-intelligence-drug-discovery #biotechnology-funding #protein-engineering #computational-drug-design
Read at Business Matters
Unable to calculate read time
Collection
[
|
...
]